{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:02:59Z","timestamp":1788408179083,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":1100,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>Hot flashes occur frequently in menopausal women and in women with breast cancer, diminishing their quality of life. A report from the Women's Health Initiative published in 2002 raised concerns about the long\u2010term safety of estrogen therapy. As a result, nonhormonal alternatives have emerged as preferred treatments. Gabapentin is an anticonvulsant that the United States Food and Drug Administration approved as an adjunct therapy for partial seizures and postherpetic neuralgia. Somnolence, dizziness, ataxia, fatigue, nystagmus, and peripheral edema are adverse effects commonly associated with gabapentin in the treatment of epilepsy and postherpetic neuralgia. The North American Menopause Society and the American College of Obstetricians and Gynecologists recommend the use of gabapentin as an option for managing hot flashes in women who are unwilling to take estrogen\u2010containing supplements. To evaluate the efficacy and safety of gabapentin for the treatment of hot flashes in women with menopause and\/or breast cancer, we performed a search of the MEDLINE database (1966\u2010March 2008) and International Pharmaceutical Abstracts, as well as manually searching reference articles for relevant articles and abstracts; 10 clinical studies were identified. Although the studies were few, all showed gabapentin to be safe and effective in the treatment of hot flashes. At doses used to control hot flashes, gabapentin was well tolerated, with drowsiness as its most reported adverse effect. Gabapentin can be considered effective in the treatment of hot flashes and should be considered a reasonable alternative when estrogen therapy is not desired.<\/jats:p>","DOI":"10.1592\/phco.29.1.74","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T08:33:41Z","timestamp":1230539621000},"page":"74-81","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Use of Gabapentin in Patients Experiencing Hot Flashes"],"prefix":"10.1002","volume":"29","author":[{"given":"Jamie N.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy R.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00117"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.046"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2057"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.4065\/77.11.1207"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1682::AID-CNCR14>3.0.CO;2-0"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60346-3"},{"key":"e_1_2_1_8_2","volume-title":"Current diagnosis and treatment obstetrics and gynecology","author":"Nathan L.","year":"2007"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp054015"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0277-9536(00)00147-7"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/152.5.463"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02593-0"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.14.1701"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.5.537"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.GME.0000108177.85442.71"},{"issue":"4","key":"e_1_2_1_17_2","first-page":"1S","article-title":"Executive summary Hormone therapy","volume":"104","author":"American College of Obstetricians and Gynecologists Women's Health Care Physicians","year":"2004","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02005-7"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn353"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1D610"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.23.4280"},{"issue":"4","key":"e_1_2_1_22_2","first-page":"CD002978","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","author":"MacLennan A.H.","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_1_23_2","volume-title":"Neurontin (gabapentin) package insert","author":"Pfizer Pharmaceuticals, Ltd","year":"2007"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00084-3"},{"key":"e_1_2_1_25_2","unstructured":"Micromedex Healthcare Series.Drugdex evaluations: gabapentin. Available fromwww.thomsonhc.comhcslibrarianPFActionIDhcs.external.RetrieveDocumenteid72088 0001DocID1427ContentSetCodeDrugdex\u2010evals. AccessedMarch 19 2008."},{"issue":"4","key":"e_1_2_1_26_2","first-page":"106S","article-title":"Vasomotor symptoms","volume":"104","author":"American College of Obstetricians and Gynecologists Women's Health Care Physicians","year":"2004","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3180dca175"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.5390"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000222383.43913.ed"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67215-7"},{"issue":"5","key":"e_1_2_1_31_2","first-page":"S21","article-title":"Application of gabapentin in Thai women with menopausal syndrome","volume":"88","author":"Bunyaratavej N.","year":"2005","journal-title":"J Med Assoc Thai"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:BREA.0000010676.54597.22"},{"issue":"11","key":"e_1_2_1_33_2","first-page":"S240","article-title":"Gabapentin versus venlafaxine for the treatment of menopausal symptoms: a preliminary report [abstract]","volume":"88","author":"Struble E.J.","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(02)02712-6"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042192-200310030-00007"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.4065\/77.11.1159"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.11.2161"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2003.07.007"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A139"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6908.836"},{"key":"e_1_2_1_41_2","volume-title":"Treatment of vasomotor symptoms: current standards","author":"Woodcock J.","year":"2002"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.29.1.74","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.29.1.74","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:29:14Z","timestamp":1761067754000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.29.1.74"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1592\/phco.29.1.74"],"URL":"https:\/\/doi.org\/10.1592\/phco.29.1.74","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}